Hôpital Roger Salengro, CHU
Lille, France
Location status: Recruiting
Location contact
Guillaume Lefevre, MD,PhD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT04018118
Unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES) are heterogeneous regarding the organ involvements (heart, lungs, skin, .. or none), the evolutionary profiles, the response to treatments.
Underlying mechanisms are largely unknown and may associate genetic predisposing factors (germinal ? somatic?), environmental factors (alimentation, tobacco use, hormones, infections, ..) The COHESion study aims to study all clinical and biological characteristics of HE/HES patients and their evolutionary profiles, with a focus on genetic factors and the mechanisms supporting transitory or persistant chronic HE/HES (in absence of any well identified extrinsic trigger like drugs, parasitosis, ..)
Interested in participating?
Request InfoAll sexes
Observational
Lille, France
Location status: Recruiting
Guillaume Lefevre, MD,PhD
PRINCIPAL_INVESTIGATOR
There is currently no data on the natural history of unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES). Clinical practice shows that HE/SHE patients can present 4 evolutionary profiles:
A. a single flare-up of their disease, with favourable evolution spontaneously or under corticosteroid therapy, without further recurrence B. recurrent flare-ups with a variable free interval of several months to several years, with or without persistent eosinophilia between flare-ups C. a chronic disease requiring the continuation of a substantive treatment D. chronic asymptomatic HE for years: the mechanisms involved in the occurrence of possible organ damage are unknown
The primary objective of the study is to describe the frequency of the different clinical manifestations during the diagnostic and follow-up of the hypereosinophilic syndrome (HES). The primary endpoint is the frequency of the different clinical manifestations and/or organs damage related to eosinophilia.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Additional blood samples for biobanking
Time frame: 10 years
The primary objective of the study is to describe the frequency of the different clinical manifestations at diagnosis and during follow-up of the hypereosinophilic syndrome (HES/HE). The primary endpoint is the frequency of the different clinical manifestations and/or organs damage related to hypereosinophilia.
Time frame: 10 years
Frequency of the different evolutionary profiles.
Time frame: 10 years
Frequency of complications (organ damages) depending on the type of HES (idiopathic, reactive, clonal…).
Time frame: 10 years
Describe the characteristics of pediatrics HE/HES vs adult HE/HES.
Time frame: 10 years
Clinical characteristics of pediatrics HE/HES vs adult HE/HES.
Time frame: 10 years
Predisposing factors in HE/HES by various genomic approaches
Time frame: 10 years
to explore Potential predisposing factors in HE/HES: serum markers predictive of interest in eosinophilopoiesis (IL5), tissue homing (eotaxins, etc.)
Time frame: 10 years
Predisposing factors in HE/HES by various genomic approaches
Time frame: 10 years
Predisposing factors in HE/HES by various genomic approaches
Contact information is provided by the study sponsor or research team.
University Hospital, Lille
Other
Study of Clinical Profiles of Patients Followed for Chronic Hypereosinophilia and/or Hypereosinophilic Syndrome by the Creation of a National Cohort
Acronym: COHESION
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00091871
Eosinophilia, Hematologic Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT03801434
BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells
Palo Alto, California, United States
View Trial DetailsNCT01524536
Eosinophilia, Hematologic Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT00001406
Asthma, Bronchial Diseases
Bethesda, Maryland, United States
View Trial Details